Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models ...

The specific parameters defined in your label, including patient population, line of therapy, and outcomes measured, will now ...

The majority of respondents not already enrolled in the program have concerns that the program won’t survive until the point ...

Bravecto Quantum is the first FDA-approved drug that treats and prevents flea and tick infestations on dogs for a duration of ...

rs6190 helps men build muscle mass and reduce diabetes risk, but increases cholesterol levels and elevates the risk of ...